Making a Business Case for a

PARP Inhibitor in Ovarian Cancer Presented by Dan Ngo

Pharma intelligence | informa2

“Our drug is more effective than the marketed Lynparzaand late stage Rucaparib.”

Pharma intelligence | informa3

View analysis on your competitor’s data (BioMedTracker)

Rucaparib Phase II – ARIEL2 Top-Line Results

Lynparza – Phase II – Study 19 (Maintenance Study)

Pharma intelligence | informa4

See how you stack up against competitors (BioMedTracker)

Likelihood of Approvals

Pharma intelligence | informa5

Know your competitors’ plans (BioMedTracker)

Tesaro’s plans for Niraparib in ovarian cancer

Clovis’ plans for Rucaparib in ovarian cancer

Pharma intelligence | informa6

What are the advantages of PARP Inhibitors? (Datamonitor)

Pharma intelligence | informa7

How many US patients are inflicted with Ovarian Cancer? (Datamonitor)

Datamonitor forecasts that the number of diagnosed incident cases for Ovarian Cancer will grow from 23,260 in 2015 to 26,690 in 2028.

Pharma intelligence | informa8

What’s the Size of the Ovarian Market? (Datamonitor)

Datamonitor forecasts that sales of key Ovarian drugs across the US, Japan and Five major EU markets will grow from $171m in 2015 to $667m in 2023.

Pharma intelligence | informa9

How Much Money will Lynparza (PARP) Make? (Datamonitor)

Lynparza is expected to hit $182m in sales globally in 2023.

Pharma intelligence | informa10

Events Impacting the Ovarian Cancer Market (Datamonitor)

Pharma intelligence | informa11

How does my Drug Compare Clinically and Commercially? (Datamonitor)

Pharma intelligence | informa12

What is the current Ph 3 trial landscape for relapsed Ovarian cancer? (Citeline)

Pharma intelligence | informa13

What’s trial timing look like? (Citeline)

Pharma intelligence | informa14

How long will Enrolment take? (Citeline)

Pharma intelligence | informa15

Who are the top Investigators we can work with? (Citeline)

Pharma intelligence | informa16

How much can we license our Phase I drug for? (Medtrack)

Historically several Phase I oncology drugs treating ovarian cancer were able to achieve between $450m-$693m in total deal value.

Pharma intelligence | informa17

What Deal Value can I expect for a PARP Inhibitor? (Medtrack)

Notable PARP deals include Clovis’ agreement with Pfizer for PF1367338 and Medivation’s agreement with BioMarin for talazoparib (an astounding $410m upfront).

Pharma intelligence | informa18